Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV000170320 | SCV002059482 | uncertain significance | Congenital myasthenic syndrome 17 | 2021-04-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001850415 | SCV002293825 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2021-05-11 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with congenital myasthenic syndrome (PMID: 24234652). ClinVar contains an entry for this variant (Variation ID: 189820). Experimental studies have shown that this variant affects LRP4 protein function (PMID: 24234652). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces glutamic acid with lysine at codon 1233 of the LRP4 protein (p.Glu1233Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. |
Fulgent Genetics, |
RCV001850415 | SCV005683184 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2024-03-30 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000170320 | SCV000222707 | pathogenic | Congenital myasthenic syndrome 17 | 2014-04-01 | no assertion criteria provided | literature only |